Myriad Genetics, Inc. News Releases https://investor.myriad.com/ Myriad Genetics, Inc. News Releases en Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer https://investor.myriad.com/news-releases/news-release-details/myriad-announces-publication-first-comprehensive-economic-study Findings Show EndoPredict Was Significantly More Cost Effective than Oncotype DX™ SALT LAKE CITY, June 25, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first Tue, 25 Jun 2019 07:05:09 -0400 Myriad Genetics, Inc. News Releases 20481 Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-receives-second-insurance-reimbursement-decision BRACAnalysis Is Now Indicated as a Companion Diagnostic for Lynparza® (olaparib) in Women with Ovarian Cancer SALT LAKE CITY, June 19, 2019 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry Wed, 19 Jun 2019 07:05:16 -0400 Myriad Genetics, Inc. News Releases 20476 Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-present-2019-goldman-sachs-global-healthcare SALT LAKE CITY, June 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 11:40 a.m. Wed, 05 Jun 2019 07:05:09 -0400 Myriad Genetics, Inc. News Releases 20461 Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-announces-new-results-two-large-studies-its SALT LAKE CITY, June 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two studies of the myRisk ® Hereditary Cancer test will be featured today in presentations at the annual meeting of Mon, 03 Jun 2019 07:05:13 -0400 Myriad Genetics, Inc. News Releases 20456 BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib) https://investor.myriad.com/news-releases/news-release-details/bracanalysis-cdxr-companion-diagnostic-test-identifies-patients NCCN Guidelines Recommend Genetic Testing for All Patients with Pancreatic Cancer SALT LAKE CITY, June 02, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its BRACAnalysis CDx ® companion diagnostic test effectively identified Sun, 02 Jun 2019 09:00:14 -0400 Myriad Genetics, Inc. News Releases 20451 Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-present-multiple-studies-2019-american-society SALT LAKE CITY, May 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at the 2019 American Society of Clinical Oncology (ASCO) annual meeting to be held May 31 to June 4, 2019 in Tue, 14 May 2019 07:04:49 -0400 Myriad Genetics, Inc. News Releases 20446 New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy https://investor.myriad.com/news-releases/news-release-details/new-publication-shows-endopredictr-test-identifies-women-early New Study Finds Approximately 62 Percent of Women May Not Need Extended Endocrine Therapy Five Years After Diagnosis SALT LAKE CITY, May 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the EndoPredict ® test (EPclin) Thu, 09 May 2019 07:04:48 -0400 Myriad Genetics, Inc. News Releases 20441 Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-reports-fiscal-third-quarter-2019-financial Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today Tue, 07 May 2019 16:04:56 -0400 Myriad Genetics, Inc. News Releases 20416 Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight® https://investor.myriad.com/news-releases/news-release-details/myriad-announces-coverage-decision-krogerr-prescription-plans-0 Agreement Also Includes In-store Interventions at Kroger Pharmacies Nationwide SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide GeneSight ® as an benefit Wed, 01 May 2019 16:05:16 -0400 Myriad Genetics, Inc. News Releases 20406 Myriad Genetics to Present at Two Upcoming Healthcare Conferences https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-present-two-upcoming-healthcare-conferences-1 SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer, will present at the Bank of Wed, 01 May 2019 07:05:09 -0400 Myriad Genetics, Inc. News Releases 20391